Antimicrobial Resistance
Bacterial antimicrobial resistance directly caused an estimated 1.27 million deaths in 2019 and was associated with 4.95 million more — placing AMR among the top global causes of mortality, ahead of HIV and malaria combined. The Lancet projects 1.91 million directly attributable deaths a year by 2050 on current trends.
Key insights
AMR mortality already at HIV+TB levels
The 2022 Lancet GRAM study put bacterial AMR among the top three causes of mortality globally. Six pathogens — E. coli, S. aureus, K. pneumoniae, S. pneumoniae, A. baumannii, P. aeruginosa — accounted for 73% of AMR deaths. Lower respiratory tract and intra-abdominal infections were the most lethal sites. Sub-Saharan Africa carries the highest age-standardised burden.
Consumption drives selection pressure
Global human antibiotic consumption rose ~46% between 2000 and 2018. Veterinary use exceeds human use in tonnes — roughly 100,000 tonnes a year globally — concentrated in intensive livestock production. The EU banned growth-promoter antibiotics in 2006; the US restricted them in 2017. China cut veterinary use by ~50% from 2015 peaks. India remains the largest single human-antibiotic consumer.
The development pipeline is thin
Only 13 new antibiotics have won marketing authorisation since mid-2017, and WHO counts just two of them as a genuinely new chemical class. The economics are broken — society wants new antibiotics held in reserve, which destroys the commercial case for development. Pull incentives (UK NHS subscription model, US PASTEUR Act proposals) are emerging. Most pipeline candidates target gram-negative resistance, which is the highest WHO priority area.
Annual deaths — major causes (latest available)
Global deaths, millions
Show data table
| Deaths (millions) | |
|---|---|
| IHD | 8.9 |
| Stroke | 6.2 |
| COPD | 3.2 |
| AMR-associated | 4.95 |
| Lower resp inf | 2.5 |
| COVID-19 (2022) | 1.2 |
| Dementia | 1.8 |
| Diabetes | 1.5 |
| HIV | 0.6 |
| TB | 1.2 |
| Malaria | 0.6 |
Key Finding: Bacterial AMR-associated mortality (4.95M) already exceeds HIV/AIDS, TB and malaria combined.
Human antibiotic consumption — selected countries
Defined daily doses per 1,000 inhabitants per day
Show data table
| DDD/1,000/day | |
|---|---|
| Greece | 35 |
| France | 24 |
| Spain | 23 |
| Italy | 21 |
| Belgium | 21 |
| UK | 18 |
| USA | 16 |
| Germany | 12 |
| Sweden | 11 |
| Netherlands | 9 |
Key Finding: Greece, France and Spain lead consumption among the countries shown; the Netherlands and Sweden run notably tight stewardship.
Methodology & caveats
Attributable vs associated deaths
GRAM distinguishes deaths directly attributable to AMR (would not have occurred with a fully susceptible pathogen) from deaths associated with AMR (occurred in someone with a resistant infection, but causal attribution is uncertain). The two estimates bracket the true burden.
Surveillance gaps
WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) collected data from 127 countries in 2024 but coverage is patchy in low-income settings. Many AMR deaths in sub-Saharan Africa are modelled from a small number of sentinel sites; uncertainty intervals are wide.
Veterinary use limits
Total antibiotic mass used in livestock exceeds human use, but per-kilogram tissue treated the figures are comparable. The fraction of human resistance traceable to veterinary use is contested — molecular epidemiology suggests it's significant for some pathogen-drug combinations (colistin/E. coli) and minor for others. The One Health approach treats human, animal and environmental use as a single system.
Why the headline is a model, not a count
No country counts resistant-infection deaths directly. The GRAM study combined hospital microbiology records, literature and modelling for 204 countries, assuming a counterfactual either of no infection (the 4.95 million) or of a drug-susceptible infection (the 1.27 million). Neither is observed. A follow-up in The Lancet in 2024 revised the series and forecast about 39 million attributable deaths between 2025 and 2050. Totals change between rounds partly because methods and pathogen coverage change.
What would change the picture
Trends differ sharply by age: child deaths from AMR fell after 1990 while deaths in over-70s rose, so ageing alone will raise the total. Better vaccines, sanitation and infection control reduce demand for antibiotics, while pull incentives could revive the pipeline. The GRAM forecast suggests better care and access to antibiotics could avert more deaths than new drugs alone, because many patients in poor countries die for lack of any effective treatment rather than from resistance.
Cite this page
GlobeChart. “Antimicrobial Resistance.” Last updated 2026-10-31. https://globechart.com/health/antimicrobial-resistance/
Please also credit the original publisher named under each chart: Murray et al., Lancet 2022 (GRAM); WHO Global Health Estimates; WHO GLASS-AMC, OECD Health Statistics 2024. Spotted an error? Tell us.